FibroScan

®

Expert

630

From installation to training and local support, we provide you with the highest quality of services.

*SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.

1.Stefanescu H, et al. A novel spleen-dedicated stiffness measurement by FibroScan improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228.
2. Dajti, Elton et al. “A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.” The American journal of gastroenterology vol. 117,11 (2022): 1825-1833. doi:10.14309/ajg.0000000000001887.
3. Baveno VII – R. de Franchis et al. Renewing consensus in portal hypertension. Journal of hepatology vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022.

The FibroScan^® Expert 630 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™ ) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan^® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan^® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan^® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available with SmartExam capability.